Literature DB >> 1657846

Characterization of an etoposide-resistant human K562 cell line, K/eto.

I Sugawara1, T Iwahashi, K Okamoto, Y Sugimoto, H Ekimoto, T Tsuruo, T Ikeuchi, S Mori.   

Abstract

An etoposide-resistant K562 cell line (K/eto) was obtained by stepwise exposure, in culture, to increasing concentrations of etoposide, without the use of mutagens. This cell line was resistant to etoposide, and slightly resistant to adriamycin, but sensitive to anti-cancer drugs such as camptothecin, vincristine, actinomycin D and so on. P-Glycoprotein, the mdr1 gene product, was not detected in this cell line, as assessed by immunocytochemistry, immunoprecipitation and flow cytometry. Overexpression of mdr1 mRNA was also not found. Interestingly, expression of 85 kD protein recognized by MRK 20 monoclonal antibody was noted. The level of DNA topoisomerase II protein, detected by antibody staining, decreased concomitantly with a general decrease in DNA topoisomerase II unknotting activity, while DNA topoisomerase I activity was not affected. Cellular accumulation of [3H]etoposide was reduced by 75% in the resistant line compared with parental K562. Karyotype analysis showed that the number of chromosomes in K/eto was 55 and neither a homogeneous staining region nor double-minute chromosomes were detected. These results indicate that this resistance is not due to an altered interaction between the drug and cellular transport machinery, i.e. MDR1, associated with the "classic" multiple drug resistance phenotype, but rather is due to the existence of other mechanism(s) of resistance, decreased transport of the drug and decreased target enzyme, DNA topoisomerase II.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657846      PMCID: PMC5918605          DOI: 10.1111/j.1349-7006.1991.tb01940.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  38 in total

1.  Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies.

Authors:  H Hamada; T Tsuruo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

2.  mRNA phenotyping by enzymatic amplification of randomly primed cDNA.

Authors:  K E Noonan; I B Roninson
Journal:  Nucleic Acids Res       Date:  1988-11-11       Impact factor: 16.971

3.  Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16.

Authors:  I Sugawara; I Kataoka; Y Morishita; H Hamada; T Tsuruo; S Itoyama; S Mori
Journal:  Cancer Res       Date:  1988-04-01       Impact factor: 12.701

4.  Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.

Authors:  M K Danks; C A Schmidt; M C Cirtain; D P Suttle; W T Beck
Journal:  Biochemistry       Date:  1988-11-29       Impact factor: 3.162

5.  Development and cross-resistance characteristics of a subline of P388 leukemia resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide.

Authors:  R K Johnson; W S Howard
Journal:  Eur J Cancer Clin Oncol       Date:  1982-05

6.  Genetic, biochemical, and cross-resistance studies with mutants of Chinese hamster ovary cells resistant to the anticancer drugs, VM-26 and VP16-213.

Authors:  R S Gupta
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

7.  Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability.

Authors:  J R Riordan; V Ling
Journal:  J Biol Chem       Date:  1979-12-25       Impact factor: 5.157

8.  Characterization of a K562 multidrug-resistant cell line.

Authors:  S Yanovich; R E Hall; D A Gewirtz
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

9.  Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification.

Authors:  D W Shen; A Fojo; J E Chin; I B Roninson; N Richert; I Pastan; M M Gottesman
Journal:  Science       Date:  1986-05-02       Impact factor: 47.728

10.  Drug sensitivity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia.

Authors:  M Odaimi; B S Andersson; K B McCredie; M Beran
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

View more
  4 in total

Review 1.  Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro.

Authors:  B T Hill
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

2.  Monitoring the expression profiles of doxorubicin-resistant K562 human leukemia cells by serial analysis of gene expression.

Authors:  Yoshikazu Ichikawa; Makoto Hirokawa; Namiko Aiba; Naohito Fujishima; Atsushi Komatsuda; Hirobumi Saitoh; Masaaki Kume; Ikuo Miura; Ken-ichi Sawada
Journal:  Int J Hematol       Date:  2004-04       Impact factor: 2.490

3.  Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.

Authors:  M K Ritke; D Roberts; W P Allan; J Raymond; V V Bergoltz; J C Yalowich
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

4.  Primer-dependent amplification of mdr1 mRNA by polymerase chain reaction.

Authors:  I Sugawara; M Watanabe; A Masunaga; S Itoyama; K Ueda
Journal:  Jpn J Cancer Res       Date:  1992-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.